CD79A

Across TCGA pan-cancer cohorts, CD79A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD79A data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD79A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD79A expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where CD79A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.766	0.486	<.001	35	view →
PDAC	OS	Median	All	0.378	0.627	.009	8	view →
HNSC	DFS	Median	II,III,IV	0.897	0.973	.025	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD79A–LUAD (DFS)

Open the LUAD breakdown →